Compare NTST & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | SRPT |
|---|---|---|
| Founded | 2019 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 2000 |
| Metric | NTST | SRPT |
|---|---|---|
| Price | $21.50 | $15.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 29 |
| Target Price | $22.02 | ★ $25.85 |
| AVG Volume (30 Days) | 1.4M | ★ 3.0M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | 0.12 | ★ 2.88 |
| Revenue | $195,006,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $16.25 | N/A |
| P/E Ratio | $179.75 | ★ $5.42 |
| Revenue Growth | ★ 19.79 | 15.58 |
| 52 Week Low | $17.02 | $14.68 |
| 52 Week High | $22.47 | $25.32 |
| Indicator | NTST | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 32.80 |
| Support Level | $21.15 | N/A |
| Resistance Level | $22.26 | $18.16 |
| Average True Range (ATR) | 0.54 | 0.80 |
| MACD | -0.08 | -0.24 |
| Stochastic Oscillator | 28.79 | 1.16 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.